Graeme Currie
Corporate Officer/Principal at PASITHEA THERAPEUTICS CORP.
Net worth: - $ as of 2024-06-29
Graeme Currie active positions
Companies | Position | Start | End |
---|---|---|---|
PASITHEA THERAPEUTICS CORP. | Corporate Officer/Principal | 2022-06-21 | - |
Career history of Graeme Currie
Former positions of Graeme Currie
Companies | Position | Start | End |
---|---|---|---|
LYTIX BIOPHARMA | Corporate Officer/Principal | 2020-12-31 | 2023-05-31 |
Alpha-5 Integrin LLC
Alpha-5 Integrin LLC Pharmaceuticals: MajorHealth Technology Part of Pasithea Therapeutics Corp., Alpha-5 Integrin LLC is a company that develops monoclonal antibody for the treatment of amyotrophic lateral sclerosis and neurodegenerative diseases. The company is based in South San Francisco, CA. The CEO of the company is Graeme Currie. Alpha-5 Integrin was acquired by Pasithea Therapeutics Corp. on June 22, 2022 for $3.29 million. | Chief Executive Officer | 2020-12-31 | 2022-05-31 |
Tolerion, Inc.
Tolerion, Inc. Pharmaceuticals: MajorHealth Technology Tolerion, Inc. operates as a clinical-stage biopharmaceutical firm. It develops and commercializes therapeutics. The firm provides TOL-3034 and TOL-3052 to treat myasthenia gravis and neuromyelitis optica. The company was founded by Lawrence J. Steinman and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 2018-12-31 | 2020-12-31 |
Rainier Therapeutics, Inc.
Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | Chief Operating Officer | 2016-12-31 | 2018-12-31 |
PDL BIOPHARMA, INC. | Chief Tech/Sci/R&D Officer | 2005-09-30 | - |
GILEAD SCIENCES, INC. | Chief Tech/Sci/R&D Officer | - | - |
Training of Graeme Currie
University of Aston | Doctorate Degree |
Statistics
International
United States | 6 |
United Kingdom | 2 |
Norway | 2 |
Operational
Corporate Officer/Principal | 3 |
Chief Tech/Sci/R&D Officer | 2 |
Doctorate Degree | 1 |
Sectoral
Health Technology | 7 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
GILEAD SCIENCES, INC. | Health Technology |
LYTIX BIOPHARMA | Health Technology |
Private companies | 5 |
---|---|
PDL BioPharma, Inc.
PDL BioPharma, Inc. BiotechnologyHealth Technology PDL BioPharma, Inc. engages in the business of developing innovative therapeutics and healthcare technologies. It operates under the Medical Devices and Income Generating Assets segments. The Medical Devices segment focuses on the sale and lease of the LENSAR laser system which includes equipment, patient interface devices, procedure licenses, training, installation, warranty, and maintenance agreements. The Income Generating Assets segment offers notes and other long-term receivables; royalty rights, hybrid notes, and royalty receivables; equity investments; and royalties from issued patents covering the humanization of antibodies. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Reno, NV. | Health Technology |
Rainier Therapeutics, Inc.
Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | Health Technology |
Tolerion, Inc.
Tolerion, Inc. Pharmaceuticals: MajorHealth Technology Tolerion, Inc. operates as a clinical-stage biopharmaceutical firm. It develops and commercializes therapeutics. The firm provides TOL-3034 and TOL-3052 to treat myasthenia gravis and neuromyelitis optica. The company was founded by Lawrence J. Steinman and is headquartered in South San Francisco, CA. | Health Technology |
Pasithea Therapeutics Corp. | |
Alpha-5 Integrin LLC
Alpha-5 Integrin LLC Pharmaceuticals: MajorHealth Technology Part of Pasithea Therapeutics Corp., Alpha-5 Integrin LLC is a company that develops monoclonal antibody for the treatment of amyotrophic lateral sclerosis and neurodegenerative diseases. The company is based in South San Francisco, CA. The CEO of the company is Graeme Currie. Alpha-5 Integrin was acquired by Pasithea Therapeutics Corp. on June 22, 2022 for $3.29 million. | Health Technology |
- Stock Market
- Insiders
- Graeme Currie
- Experience